High-dose, post-transplant cyclophosphamide can successfully reduce severe graft-versus-host disease (GVHD) after T-cell-replete allogeneic transplantation for AML, ALL, and MDS, using related and unrelated donors. This retrospective study included 209 adults who underwent myeloablative transplantation and received post-transplant cyclophosphamide as the sole GVHD prophylaxis. Cumulative incidences of grades II-IV and grades III-IV acute GVHD at 100 days were 45% and 11%, respectively, and chronic GVHD at 2 years was 13%. Forty-three percent of patients did not require immunosuppression for any reason beyond post-transplant cyclophosphamide. Transplant-related mortality at 3 years was 15%, which Dr. Olle Ringdén noted in an editorial discussing the study was much lower than what is generally seen with a calcineurin inhibitor combined with a short arm of methotrexate.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Post-HCT Cyclophosphamide is Effective as Sole GVHD Prophylaxis
Dec 2014